FOLD

NEUTRALM&A

Amicus Therapeutics, Inc.

2026-04-06

Price

$14.45

+0.07%

Score7.2Priority

Signals5/8 DNA2/13 Act · 0/4 Risk

SentimentNEUTRALScore: 7

Volume0.6xvs 20d avg

Analysis

FOLD's exceptionally low realized volatility (1.9%) and flat price action are the direct result of a pending $4.8 billion all-cash acquisition by BioMarin at $14.50 per share. The technical signals—QUIET_STORM and STEADY_CLIMB—perfectly capture this merger arbitrage dynamic, as the stock slowly pins to the buyout price following shareholder approval in March 2026. Furthermore, the RISK_ON macro regime and ultra-low corporate credit spreads (0.86%) provide immense conviction that BioMarin's debt financing is highly secure, virtually eliminating deal-break risk. Ultimately, the stock is no longer trading on organic fundamentals but is simply running down the clock to the Q2 2026 close.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSPERFECT STACKSELLER FATIGUEINSIDE OUT

Key Takeaways

Merger Arbitrage Pin: FOLD is trading at $14.45, leaving a minimal 5-cent spread to the $14.50 all-cash acquisition price from BioMarin [2.1].
Risk Subdued by Macro: The RISK_ON regime and compressing credit spreads virtually eliminate financing risk for the buyer, locking in the deal's certainty.
Wait for Close: With shareholder approval already secured in March 2026, the only remaining catalyst is the official deal closure expected in Q2 2026.

← Back to 2026-04-06 View Full FOLD History →Yahoo Finance &nearr;